Sugi Predict

Sugi Predict / Targets / TNF

TNF

Tumor necrosis factor · P01375 · TNF on Sugi Atlas →

135,444 patent compounds predicted against TNF, 82,031 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Cdc-801 Cdc-801 (SCHEMBL185853) 0.77 11/20
Doramapimod Doramapimod (SCHEMBL129721) 1.00 7/20
SCHEMBL62843 SCHEMBL62843 0.58 6/20
SCHEMBL69209 SCHEMBL69209 0.58 6/20
SCHEMBL62525 SCHEMBL62525 0.56 6/20
SCHEMBL62400 SCHEMBL62400 0.55 6/20
SCHEMBL61757 SCHEMBL61757 0.51 6/20
SCHEMBL60346 SCHEMBL60346 0.51 6/20
SCHEMBL62041 SCHEMBL62041 0.51 6/20
SCHEMBL62126 SCHEMBL62126 0.51 6/20
SCHEMBL68285 SCHEMBL68285 0.51 6/20
SCHEMBL68778 SCHEMBL68778 0.51 6/20
SCHEMBL70107 SCHEMBL70107 0.51 6/20
SCHEMBL70133 SCHEMBL70133 0.51 6/20
SCHEMBL70102 SCHEMBL70102 0.55 5/20
SCHEMBL70126 SCHEMBL70126 0.55 5/20
SCHEMBL69194 SCHEMBL69194 0.54 5/20
SCHEMBL70131 SCHEMBL70131 0.54 5/20
SCHEMBL62299 SCHEMBL62299 0.53 5/20
SCHEMBL69198 SCHEMBL69198 0.48 5/20

Clinical trials — most relevant to TNF by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis PHASE4WITHDRAWN
Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders PHASE4UNKNOWN
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) PHASE4COMPLETED
Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies PHASE2/PHASE3COMPLETED
Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis PHASE3COMPLETED
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis PHASE3COMPLETED
Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis PHASE3COMPLETED
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease PHASE3COMPLETED
Etanercept in Hidradenitis Suppurativa PHASE2COMPLETED
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions) PHASE2COMPLETED
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I) PHASE2RECRUITING
Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction PHASE2COMPLETED
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial PHASE1UNKNOWN
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease PHASE1COMPLETED
Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94 PHASE1COMPLETED
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Functional Implications of TNF nanCOMPLETED
A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis nanNOT_YET_RECRUITING
Acupuncture for Reduction of Inflammation nanCOMPLETED
Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis nanCOMPLETED
Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis nanUNKNOWN
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis nanNOT_YET_RECRUITING
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients nanRECRUITING
Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis nanUNKNOWN
Post-surgery Systemic Inflammation and Neuro-immune Interactions nanCOMPLETED
Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease nanCOMPLETED
Effects of Cold Exposure and Breathing Techniques on Immune Response nanCOMPLETED
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis nanACTIVE_NOT_RECRUITING
The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis nanUNKNOWN
EVALUATION OF SALIVARY BİOMARKER LEVELS IN SMOKING AND NON-SMOKER INDIVIDUALS WITH DIFFERENT PERIODONTAL DISEASES nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TNF binder may also engage these)

ProteinNameSimilarity
Q9BEA1 — 1.000 Q9BEA1 →
P33620 — 1.000 P33620 →
P48094 — 1.000 P48094 →
O77510 — 1.000 O77510 →
P51742 — 1.000 P51742 →
Q8HZD9 — 1.000 Q8HZD9 →
P59695 — 1.000 P59695 →
Q8WNR1 — 1.000 Q8WNR1 →
P19101 — 1.000 P19101 →
P29553 — 1.000 P29553 →
P36939 — 1.000 P36939 →
P23563 — 1.000 P23563 →
Q75N23 — 1.000 Q75N23 →
P59693 — 1.000 P59693 →
P23383 — 1.000 P23383 →
P79337 — 1.000 P79337 →
Q1G1A2 — 1.000 Q1G1A2 →
P06804 — 1.000 P06804 →
Q8MKG8 — 1.000 Q8MKG8 →
Q19LH4 — 1.000 Q19LH4 →
Q539C2 — 1.000 Q539C2 →
P04924 — 1.000 P04924 →
P51743 — 1.000 P51743 →
P59694 — 1.000 P59694 →
P13296 — 1.000 P13296 →
P51435 — 1.000 P51435 →
O77764 — 1.000 O77764 →
P16599 — 1.000 P16599 →
Q06599 — 0.999 Q06599 →
Q2MH05 — 0.999 Q2MH05 →